Allergic rhinitis. Vasomotor and allergic rhinitis
Conditions
Interventions
Intervention 1: First intervention group: treated with budesonide nasal spray by Jaber Ibn Hayyan Company (1 puff of spray 64 micrograms per nose, morning and evening
a total of 256 micrograms per day) for 3 months. Intervention 2: Second intervention group: treated with montelukast tablets produced by Tehran Daru company (1 montelukast tablet 10 mg in the evening)
a total of 128 micrograms per day) plus montelukast tablets produced by Tehran Daroo Company (1 montelukast tablets 10 mg in the evening) for 3 months.
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
15 Years to No maximum
Inclusion criteria
Inclusion criteria: Having allergic rhinitis Age over 15 years
Exclusion criteria
Exclusion criteria: smoking Pregnancy Asthma Nasal polyps Severe nasal deviation Nasal tumor or mass Sinusitis Get any treatment for allergic rhinitis within a week before the visit Existence of severe underlying disease Having Churg-Strauss
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Runny nose score. Timepoint: Before intervention, 3 weeks, 6 weeks and 12 weeks after treatment. Method of measurement: Visual Analogue Scale and Sino-nasal Outcome Test questionnaires.;Sneezing score. Timepoint: Before intervention, 3 weeks, 6 weeks and 12 weeks after treatment. Method of measurement: Visual Analogue Scale and Sino-nasal Outcome Test questionnaires.;Nasal congestion score. Timepoint: Before intervention, 3 weeks, 6 weeks and 12 weeks after treatment. Method of measurement: Visual Analogue Scale and Sino-nasal Outcome Test questionnaires.;Itchy nose score. Timepoint: Before intervention, 3 weeks, 6 weeks and 12 weeks after treatment. Method of measurement: Visual Analogue Scale and Sino-nasal Outcome Test questionnaires. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAhmad Rezaeian
Esfahan University of Medical Sciences
Outcome results
None listed